Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress

por Chergui, Adel, Reagan, John L.
Publicado 2023

Use of cellular immunotherapy for treatment of refractory acute myeloid leukemia

por Fast, Loren, Reagan, John, Quesenberry, Peter
Publicado 2013

Plasmablastic Lymphoma: A Systematic Review

por Castillo, Jorge J., Reagan, John L.
Publicado 2011

The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia

por Egan, Pamela C, Reagan, John L
Publicado 2018

Pruritic Rash in a Patient with Hodgkin's Lymphoma

por Le, Audrey, Farmakiotis, Dimitrios, Reagan, John L
Publicado 2018

Rhomboid glossitis in disseminated CMV infection

por Black, Robert C., Reagan, John, Taliano, Ross, Farmakiotis, Dimitrios
Publicado 2017

Use of bone‐modifying agents and clinical outcomes in older adults with multiple myeloma

por Olszewski, Adam J., Barth, Peter M., Reagan, John L.
Publicado 2019

Induction of anti-leukemic responses by stimulation of leukemic CD3+ cells with allogeneic stimulator cells

por Pando, Alejandro, Reagan, John L., Nevola, Martha, Fast, Loren D.
Publicado 2018

Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia

por Hsu, Andrew, Liu, Yuchen, Zayac, Adam S., Olszewski, Adam J., Reagan, John L.
Publicado 2020

Murine Leukemia-Derived Extracellular Vesicles Elicit Antitumor Immune Response

por Pando, Alejandro, Fast, Loren, Dubielecka, Patrycja M, Chorzalska, Anna, Wen, Sicheng, Reagan, John
Publicado 2021

Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies

por Reagan, John L., Fast, Loren D., Winer, Eric S., Safran, Howard, Butera, James N., Quesenberry, Peter J.
Publicado 2012

Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study

por Pelcovits, Ari, Barth, Peter, Reagan, John L, Olszewski, Adam J, Rosati, Vallerie, Wood, Roxanne, Sturtevant, Ashlee, Winer, Eric S
Publicado 2023

Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study

por Ollila, Thomas, Butera, James, Egan, Pamela, Reagan, John, Thomas, Anthony, Yakirevich, Inna, MacKinnon, Kelsey, Margolis, Jeannine, McMahon, Jessica, Rosati, Valerie, Olszewski, Adam J
Publicado 2022

Cellular immunotherapy for refractory hematological malignancies

por Reagan, John L, Fast, Loren D, Safran, Howard, Nevola, Martha, Winer, Eric S, Castillo, Jorge J, Butera, James N, Quesenberry, Matthew I, Young, Carolyn T, Quesenberry, Peter J
Publicado 2013

Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies

por Ollila, Thomas A., Masel, Rebecca, Reagan, John L, Paiva, Kimberly, Lu, Shaolei, Rogers, Ralph, Zayac, Adam, Taher, Rashida, Yakirevich, Inna, Niroula, Rabin, Barth, Peter, Olszewski, Adam J.
Publicado 2021

Potential biomarkers to detect traumatic brain injury by the profiling of salivary extracellular vesicles

por Cheng, Yan, Pereira, Mandy, Raukar, Neha, Reagan, John L., Queseneberry, Mathew, Goldberg, Laura, Borgovan, Theodor, LaFrance, W Curt, Dooner, Mark, Deregibus, Maria, Camussi, Giovanni, Ramratnam, Bharat, Quesenberry, Peter
Publicado 2019

Inflammation-related gene expression profiles of salivary extracellular vesicles in patients with head trauma

por Cheng, Yan, Pereira, Mandy, Raukar, Neha P., Reagan, John L., Quesenberry, Mathew, Goldberg, Laura, Borgovan, Theodor, LaFrance Jr, W Curt, Dooner, Mark, Deregibus, Maria, Camussi, Giovanni, Ramratnam, Bharat, Quesenberry, Peter
Publicado 2019

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

por Martin, Peter, Bartlett, Nancy L., Chavez, Julio C., Reagan, John L., Smith, Sonali M., LaCasce, Ann S., Jones, Jeffrey, Drew, James, Wu, Chengqing, Mulvey, Erin, Revuelta, Maria V., Cerchietti, Leandro, Leonard, John P.
Publicado 2022

Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl induced leukemia

por Chorzalska, Anna, Salloum, Ibrahem, Shafqat, Hammad, Khan, Saad, Marjon, Philip, Treaba, Diana, Schorl, Christoph, Morgan, John, Bryke, Christine R., Falanga, Vincent, Zhao, Thing C., Reagan, John, Winer, Eric, Olszewski, Adam, Al-Homsi, Samer, Kouttab, Nicola, Dubielecka, Patrycja M.
Publicado 2014

Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia

por Chorzalska, Anna, Ahsan, Nagib, Rao, R. Shyama Prasad, Roder, Karim, Yu, Xiaoqing, Morgan, John, Tepper, Alexander, Hines, Steven, Zhang, Peng, Treaba, Diana O., Zhao, Ting C., Olszewski, Adam J., Reagan, John L., Liang, Olin, Gruppuso, Philip A., Dubielecka, Patrycja M.
Publicado 2018